NDAINTRAMUSCULARPOWDER
Approved
Mar 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZYPREXA (olanzapine) by Aurobindo Pharma is olanzapine, in the listed indications is unclear. Approved for schizophrenia, bipolar disorder, schizoaffective disorder and 1 more indications. First approved in 2004.
Drug data last refreshed 1w ago
Mechanism of Action
olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
Pharmacologic Class:
Atypical Antipsychotic
Indications (4)
Worked on ZYPREXA at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.